B
Bull
Bull · 25%PHAR
$11.40
Scenario price
$9.360
-0.262 (-2.80%)At close
Loading chart…
- High
- 9.515
- Open
- 9.500
- VWAP
- 9.40
- Volume
- 9.03K
- Mkt Cap
- 529.32M
- Low
- 9.310
- Amount
- 84.83K
- EV/EBITDA, TTM
- 35.02
Pharming Group NV is a biopharmaceutical company based in the Netherlands. The Company is engaged in the development, production and commercialization of human therapeutic proteins to be used in the therapies. The Company's product portfolio is aimed at treatments for genetic disorders, blood-related disorders, infectious and inflammatory diseases, tissue and bone damage and surgical/traumatic bleeding. Its core product, RUCONEST (conestat alfa) is a recombinant human C1 esterase inhibitor approved for the treatment of acute Hereditary Angioedema (HAE) attacks in patients in Europe, the Unites States, Israel and South Korea. The product is available on a named-patient basis in other territories where it has not yet obtained marketing authorization.
AI analysis of Pharming Group NV (PHAR)
SellPharming Group NV is not a good buy right now due to its current price of $9.36, which is significantly below the analyst price target range of $37 to $40. Additionally, the stock has a high forward P/E ratio of 212.77, indicating overvaluation concerns. The RSI is at 30.07, suggesting the stock is oversold, but this could indicate further downside risk rather than an immediate buying opportunity.
Valuation Metrics
The current forward P/E ratio for Pharming Group NV (PHAR) is 212.77, compared to its 5-year average forward P/E of -39.73.
Alphio AI Price Scenarios for PHAR
Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.
Events Timeline
News
9.010-14NewsfilterPharming Presents Positive Phase II Data for Leniolisib in Primary Immunodeficiencies
7.510-12stocktwitsBiotech Firms Set to Release Key Data This Week
9.009-25NASDAQ.COMFDA Accepts Pharming's Lower Dose Joenja Application
- 9.009-22Newsfilter
Pharming Reports Phase II Clinical Data for Leniolisib in PIDs
9.009-11NASDAQ.COMFDA Approves Joenja for Pediatric APDS Treatment
PHAR FAQ — answered by Alphio AI
Pharming Group NV is a biopharmaceutical company based in the Netherlands. The Company is engaged in the development, production and commercialization of human therapeutic proteins to be used in the therapies. The Company's product portfolio is aimed at treatments for genetic disorders, blood-related disorders, infectious and inflammatory diseases, tissue and bone damage and surgical/traumatic bleeding. Its core product, RUCONEST (conestat alfa) is a recombinant human C1 esterase inhibitor approved for the treatment of acute Hereditary Angioedema (HAE) attacks in patients in Europe, the Unites States, Israel and South Korea. The product is available on a named-patient basis in other territories where it has not yet obtained marketing authorization. It operates in the Healthcare sector.
Pharming Group NV is not a good buy right now due to its current price of $9.36, which is significantly below the analyst price target range of $37 to $40. Additionally, the stock has a high forward P/E ratio of 212.77, indicating overvaluation concerns. The RSI is at 30.07, suggesting the stock is oversold, but this could indicate further downside risk rather than an immediate buying opportunity.
Community
More ↗No posts yet
Sign up or log in to join the discussionThis page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.